Overview

Our ADP-A2M10 (MAGE-A10) T-cell therapy is directed to a highly immunogenic member of the MAGE family of cancer testis antigens expressed in a number of solid tumor cell types. Any expression in cancer is often associated with higher grade tumors.

Based on our ongoing preclinical evaluation, we believe our ADP-A2M10 T-cell therapeutic candidate has the potential ability to bind target peptides from multiple cancer types. We have two ongoing clinical trials to evaluate the safety and anti- tumor activity of ADP-A2M10: one with non-small cell lung cancer, and one with bladder, melanoma and head and neck cancers.

Please note that the two trials with ADP-A2M10 will be closed for enrollment by end of 2019.

Our Trials

ADP-A2M10 Non-Small Cell Lung Cancer Clinical Trial

This is a Phase I, open label, dose escalation clinical trial designed to evaluate the safety and anti-tumor activity of Adaptimmune's ADP-A2M10 (MAGE-A10) therapeutic candidate in patients who are HLA-A*02 positive and have advanced (Stage IIIb or Stage IV) or recurrent non-small cell lung cancer (NSCLC) that expresses MAGE-A10. The primary objective of the clinical trial is to evaluate the safety and tolerability of ADP-A2M10 SPEAR T-cell therapy. Further details are available via the link below.

View Clinical Trial

ADP-A2M10 Triple Tumor Clinical Trial

This is a Phase I, open label, dose escalation clinical trial designed to evaluate the safety and anti-tumor activity of Adaptimmune's ADP- A2M10 (MAGE-A10) therapeutic candidate in patients who are HLA-A*02 positive and have inoperable locally advanced or metastatic melanoma, urothelial or head and neck cancers that express MAGE- A10. The primary objective of the clinical trial is to evaluate the safety and tolerability of ADP- A2M10 SPEAR T- cell therapy. Further details are available via the link below.

View Clinical Trial

Publications

Please visit our Publications page for more information on ADP-A2M10